Literature DB >> 27553701

Phosphodiesterase 2: anti-adrenergic friend or hypertrophic foe in heart disease?

Michael Wagner1, Hind Mehel2, Rodolphe Fischmeister2, Ali El-Armouche3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27553701     DOI： 10.1007/s00210-016-1289-4

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  9 in total

1.  Opposite effects of cyclic GMP and cyclic AMP on Ca2+ current in single heart cells.

Authors:  H C Hartzell; R Fischmeister
Journal:  Nature       Date:  1986 Sep 18-24       Impact factor: 49.962

Review 2.  Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases.

Authors:  Rodolphe Fischmeister; Liliana R V Castro; Aniella Abi-Gerges; Francesca Rochais; Jonas Jurevicius; Jérôme Leroy; Grégoire Vandecasteele
Journal:  Circ Res       Date:  2006-10-13       Impact factor: 17.367

3.  Activation of PDE2 and PDE5 by specific GAF ligands: delayed activation of PDE5.

Authors:  Ronald Jäger; Frank Schwede; Hans-Gottfried Genieser; Doris Koesling; Michael Russwurm
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

4.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

5.  Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy.

Authors:  Ali El-Armouche; Katrin Wittköpper; Franziska Degenhardt; Florian Weinberger; Michael Didié; Ivan Melnychenko; Michael Grimm; Micha Peeck; Wolfram H Zimmermann; Bernhard Unsöld; Gerd Hasenfuss; Dobromir Dobrev; Thomas Eschenhagen
Journal:  Cardiovasc Res       Date:  2008-08-08       Impact factor: 10.787

6.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.

Authors:  M Packer; J R Carver; R J Rodeheffer; R J Ivanhoe; R DiBianco; S M Zeldis; G H Hendrix; W J Bommer; U Elkayam; M L Kukin
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

7.  Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes.

Authors:  Hind Mehel; Julius Emons; Christiane Vettel; Katrin Wittköpper; Danilo Seppelt; Matthias Dewenter; Susanne Lutz; Samuel Sossalla; Lars S Maier; Patrick Lechêne; Jérôme Leroy; Florence Lefebvre; Audrey Varin; Thomas Eschenhagen; Stanley Nattel; Dobromir Dobrev; Wolfram-Hubertus Zimmermann; Viacheslav O Nikolaev; Grégoire Vandecasteele; Rodolphe Fischmeister; Ali El-Armouche
Journal:  J Am Coll Cardiol       Date:  2013-06-26       Impact factor: 24.094

Review 8.  Beta-adrenergic stimulation and myocardial function in the failing heart.

Authors:  Ali El-Armouche; Thomas Eschenhagen
Journal:  Heart Fail Rev       Date:  2009-12       Impact factor: 4.214

9.  Cardiac Hypertrophy Is Inhibited by a Local Pool of cAMP Regulated by Phosphodiesterase 2.

Authors:  Anna Zoccarato; Nicoletta C Surdo; Jan M Aronsen; Laura A Fields; Luisa Mancuso; Giuliano Dodoni; Alessandra Stangherlin; Craig Livie; He Jiang; Yuan Yan Sin; Frank Gesellchen; Anna Terrin; George S Baillie; Stuart A Nicklin; Delyth Graham; Nicolas Szabo-Fresnais; Judith Krall; Fabrice Vandeput; Matthew Movsesian; Leonardo Furlan; Veronica Corsetti; Graham Hamilton; Konstantinos Lefkimmiatis; Ivar Sjaastad; Manuela Zaccolo
Journal:  Circ Res       Date:  2015-08-04       Impact factor: 17.367
  9 in total
  4 in total

1.  Phosphodiesterase PDE2 activity, increased by isoprenaline, does not reduce β-adrenoceptor-mediated chronotropic and inotropic effects in rat heart.

Authors:  Alejandro Galindo-Tovar; María Luisa Vargas; Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-19       Impact factor: 3.000

Review 2.  The Endocrine Function of the Heart: Physiology and Involvements of Natriuretic Peptides and Cyclic Nucleotide Phosphodiesterases in Heart Failure.

Authors:  Claire Lugnier; Alain Meyer; Anne Charloux; Emmanuel Andrès; Bernard Gény; Samy Talha
Journal:  J Clin Med       Date:  2019-10-21       Impact factor: 4.241

Review 3.  Therapeutic Implications for PDE2 and cGMP/cAMP Mediated Crosstalk in Cardiovascular Diseases.

Authors:  Mirna S Sadek; Eleder Cachorro; Ali El-Armouche; Susanne Kämmerer
Journal:  Int J Mol Sci       Date:  2020-10-10       Impact factor: 5.923

4.  Response to Wagner et al.: phosphodiesterase-2-anti-adrenergic friend or hypertrophic foe in heart disease?

Authors:  Anna Zoccarato; Laura H Fields; Manuela Zaccolo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-27       Impact factor: 3.000
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.